DEF: C4 Therapeutics Seeks Stockholder Approval for Increased Share Authorization and Executive Compensation

Sentiment:

Proxy Statement 29 April 2025 7:01 AM

C4 Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, approve executive compensation, ratify the appointment of KPMG LLP, and increase the number of authorized shares of common stock.

Capital raiseThe company is seeking approval to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.The additional shares would provide flexibility for future capital raising, strategic transactions, and equity compensation.

Summary

C4 Therapeutics is holding its 2025 Annual Meeting of Stockholders on June 18, 2025.
Stockholders will vote on the election of three Class II directors, an advisory vote on executive compensation, ratification of KPMG LLP as the independent auditor, and an amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares.
The Board of Directors recommends voting for all proposals.
The company highlights its 2024 achievements, including clinical data from lead programs, business development initiatives, and board evolution.
Key clinical programs include cemsidomide (IZKF1/3 degrader), CFT1946 (BRAF V600 mutant degrader), and CFT8919 (EGFR L8585R degrader).
C4 Therapeutics entered a license agreement with Merck KGaA, Darmstadt, Germany, potentially receiving up to approximately $740 million in milestone payments.
The company completed a $25 million equity investment by Betta Investment (Hong Kong) Limited and executed a corporate restructuring to extend its cash runway.
Executive compensation includes base salary, annual cash incentives, and equity incentives, with a significant portion tied to company performance.
The company's executive compensation program aims to align executive interests with stockholder returns and attract and retain qualified executives.
The Board of Directors has determined that all members of the Board of Directors, except Andrew J. Hirsch, are independent directors.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with significant achievements in clinical development, business development, and financial stability. The company is executing on its strategic objectives and has secured key partnerships.

Positives

Strong execution across clinical programs with promising data releases.
Successful business development initiatives, including the Merck KGaA agreement and Biogen collaboration.
Secured a $25 million equity investment, strengthening the company's financial position.
Proactive corporate restructuring to extend cash runway.
Board evolution with the addition of experienced directors.
Advancement of research platform with delivery of development candidates to Biogen.

Risks

The proxy statement does not explicitly detail any specific risks, but inherent risks exist in clinical-stage biopharmaceutical companies, including clinical trial failures, regulatory hurdles, and competition.
Dilution of existing stockholders' voting rights and equity is possible with the increase in authorized shares.

Future Outlook

The company plans to continue advancing its clinical programs, expanding its pipeline, and executing on partnered programs. They aim to transform patient care through protein degradation.

Management Comments

This past year was highly productive for C4 Therapeutics as we focused on execution and achieved our key strategic objectives across our entire portfolio.

Industry Context

C4 Therapeutics operates in the competitive biopharmaceutical industry, focusing on targeted protein degradation. The company's collaborations with Merck KGaA, Biogen, and Betta Pharma reflect a growing trend of partnerships in the biotech sector to leverage expertise and share development costs.

Comparison to Industry Standards

C4 Therapeutics' focus on targeted protein degradation aligns with a growing area of interest in the pharmaceutical industry, with companies like Arvinas and Kymera Therapeutics also pursuing this approach.
The potential $740 million in milestone payments from the Merck KGaA collaboration is a significant deal, comparable to other licensing agreements in the biotech space.
The company's clinical programs, including cemsidomide and CFT1946, are at similar stages of development as those of other clinical-stage biopharmaceutical companies.
The executive compensation structure, with a significant portion tied to performance, is consistent with industry standards for incentivizing management and aligning their interests with those of stockholders.

Related Party Transactions

The License and Collaboration Agreement with Betta Pharma, a holder of more than 5% of our outstanding capital stock at the time of the agreement, to collaborate on the development and commercialization of CFT8919, an orally bioavailable BiDAC degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation, in mainland China, Hong Kong SAR, Macau SAR and Taiwan, or the Territory, with us retaining rights to CFT8919 in the rest of the world.

Stakeholder Impact

Approval of the proposals would enable the company to continue its operations and strategic initiatives, potentially benefiting stockholders through increased value.
Employees would benefit from continued employment and equity incentives.
Patients could benefit from the development of new therapies.
Partners would benefit from continued collaboration and potential commercial success.

Next Steps

Stockholder vote on the proposals at the Annual Meeting on June 18, 2025.
Continued advancement of clinical programs and pipeline development.
Execution of partnered programs and potential achievement of milestone payments.

Key Dates

Date	Description
2015-12-01	Kenneth C. Anderson, M.D. co-founded and has served as a member of our Board since December 2015.
2020-07-01	Jolie M. Siegel has served as our Chief Legal Officer since July 2020
2020-09-06	We entered into an employment agreement with Mr. Hirsch, our President and Chief Executive Officer, pursuant to which Mr. Hirsch serves as our President and Chief Executive Officer.
2020-10-01	Andrew J. Hirsch has served as our Chief Executive Officer since October 2020.
2021-01-01	Kelly A. Schick has served as our Chief People Officer since January 2021.
2022-01-01	Scott N. Boyle, Ph.D., M.B.A. has served as our Chief Business Officer since January 2022.
2022-03-01	Utpal Koppikar has served as our director since March 2022.
2022-08-01	Laura Bessen, M.D., has served as our director since August 2022.
2022-08-01	Donna Grogan, M.D., has served as our director since August 2022.
2023-05-01	We entered into a license and collaboration agreement with Betta Pharma to collaborate on the development and commercialization of CFT8919 in mainland China, Hong Kong SAR, Macau SAR and Taiwan
2023-07-01	Leonard Len Reyno, M.D., has served as our Chief Medical Officer since July 2023.
2023-09-01	Kendra R. Adams has served as our Chief Financial Officer and Treasurer since September 2023
2023-11-01	Owen Hughes has served as a director since November 2023.
2024-01-01	Betta Investment completed the purchase of these shares in January 2024.
2024-03-07	Our OLCC approved and implemented a stock option repricing, or the Repricing, in accordance with the provisions of our 2020 Plan, as then in effect.
2024-03-01	We entered into a license and collaboration agreement with MKDG to exclusively discover two targeted protein degraders against critical oncogenic proteins, which we had progressed within our internal discovery pipeline.
2024-04-01	The Board of Directors declared it advisable and approved and adopted an amendment to our Fifth Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 150,000,000 to 300,000,000, or the Authorized Shares Charter Amendment.
2024-06-01	Ronald Harold Wilfred Cooper has served as our director and as Chairman of our Board of Directors since June 2024.
2024-07-01	Since July 2024, Mr. Cooper has served as Chief Executive Officer and director of enGene Holdings, Inc.
2024-08-01	We entered into an ancillary clinical supply agreement, or the Betta Pharma Supply Agreement, with Betta Pharma under which Betta Pharma purchases from us sufficient supply of CFT8919 for the clinical trial(s) it conducts in the Territory in accordance with the License Agreement.
2024-09-01	Stephen Fawell, Ph.D. has served as our director since September 2024.
2024-09-01	We entered into an ancillary safety data exchange agreement with Betta Pharma governing each partys pharmacovigilance activities in connection with the clinical trial(s) conducted by Betta Pharma in the Territory.
2024-09-01	At the European Society of Medical Oncology Congress, we presented monotherapy data from the ongoing Phase 1/2 trial, which demonstrated that CFT1946 was well tolerated with initial signs of anti-tumor activity across all dose levels.
2024-10-01	Paige Mahaney, Ph.D. has served as our Chief Scientific Officer since October 2024.
2024-10-01	Our Board of Directors approved an amendment to our 2020 Stock Option and Incentive Plan, or the 2020 Plan, to remove the Companys ability to implement a repricing of outstanding stock options in the future absent the prior receipt of stockholder approval.
2024-11-01	Betta Pharma initiated a Phase 1 clinical trial of CFT8919 in EGFR L858R NSCLC in Greater China and the trial is ongoing.
2024-11-01	Steven Hoerter has served as our director since November 2024.
2024-12-01	At the Annual Hematology Society Meeting, we shared data evaluating cemsidomide in combination with dexamethasone in MM that demonstrated a well-tolerated profile with compelling anti-myeloma activity.
2024-12-01	At the Annual Hematology Society Meeting, we shared data evaluating cemsidomide as a monotherapy in NHL that demonstrated a well-tolerated profile and compelling anti-lymphoma activity in NHL and, in particular, in PTCL.
2025-04-22	Record date for the Annual Meeting.
2025-04-29	Approximate date of mailing the Notice of Availability of Proxy Materials.
2025-06-18	Date of the 2025 Annual Meeting of Stockholders.
2025-12-30	Deadline for stockholder proposals for inclusion in the 2026 proxy statement.
2026-02-18	Earliest date for stockholder proposals to be brought before the 2026 annual meeting of stockholders.
2026-03-20	Latest date for stockholder proposals to be brought before the 2026 annual meeting of stockholders.
2026-04-19	Deadline for stockholders who intend to solicit proxies in support of director nominees other than the companys nominees to provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act.

Keywords

C4 Therapeutics, proxy statement, annual meeting, directors, executive compensation, KPMG LLP, authorized shares, cemsidomide, CFT1946, CFT8919, Merck KGaA, Biogen, Betta Pharmaceuticals, clinical trials, targeted protein degradation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.